Bausch Health Americas, Inc.
Clinical trials sponsored by Bausch Health Americas, Inc., explained in plain language.
A subsidiary of Bausch Health, focused on pharmaceuticals and medical devices in the Americas.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for kids with colitis: budesonide pill trial aims for remission Results expected Dec 2026 (estimated)
- New radiofrequency treatment aims to tighten sagging skin without surgery Results expected Feb 2027 (estimated)
- New hope for Kids' diarrhea: drug plus fluids tested Results expected Apr 2027 (estimated)
-
New drug trial for kids with severe psoriasis shows promise
Disease control OngoingThis study tests a single dose of brodalumab in children aged 6 to 17 with severe plaque psoriasis. The goal is to see how safe the drug is and how the body processes it. Only 2 children are enrolled, making this a very early look at the drug's effects in younger patients.
Phase 4 • Sponsor: Bausch Health Americas, Inc. • Aim: Disease control
Last updated Jun 26, 2026 18:44 UTC
-
Psoriasis drug brodalumab under safety spotlight in large Real-World study
Disease control By invitation onlyThis study is tracking 3500 adults with moderate-to-severe psoriasis to compare the long-term safety of brodalumab with other psoriasis treatments. Researchers are specifically looking at rates of cancer (excluding skin cancer) in people taking brodalumab versus those on other bi…
Sponsor: Bausch Health Americas, Inc. • Aim: Disease control
Last updated Jun 26, 2026 18:41 UTC
-
COVID-19 drug trial pulled before it even started
Disease control CancelledThis study planned to test an inhaled medicine called Virazole (ribavirin) in adults hospitalized with COVID-19 who had serious breathing trouble. The goal was to see if the drug was safe and could improve oxygen levels. However, the trial was withdrawn before enrolling any volun…
Phase 1 • Sponsor: Bausch Health Americas, Inc. • Aim: Disease control
Last updated Jun 26, 2026 18:13 UTC
-
New hope for liver patients: drug may delay brain fog and hospital stays
Disease control OngoingThis Phase 3 study tests whether a special form of the antibiotic rifaximin can delay the first episode of overt hepatic encephalopathy (brain dysfunction) in people with liver cirrhosis who have controlled fluid buildup in the belly. About 466 participants will receive either ri…
Phase 3 • Sponsor: Bausch Health Americas, Inc. • Aim: Disease control
Last updated Jun 26, 2026 16:50 UTC
-
New laser aims to smooth wrinkles and sun damage
Symptom relief OngoingThis study is testing a next-generation Fraxel laser system to see how well it improves skin issues like sun damage, lesions, and wrinkles around the eyes. About 49 adults aged 21 to 60 will receive up to three laser treatments. Researchers will check for improvements using a doc…
Sponsor: Bausch Health Americas, Inc. • Aim: Symptom relief
Last updated Aug 30, 2026 00:00 UTC
-
Can a Once-Daily pill ease chronic constipation in kids?
Symptom relief OngoingThis trial tests whether plecanatide, a drug taken by mouth once a day, can safely improve bowel movements in children and adolescents aged 6 to 17 with functional constipation. Participants receive either low-dose plecanatide, high-dose plecanatide, or a placebo for 8 weeks. The…
Phase 2 • Sponsor: Bausch Health Americas, Inc. • Aim: Symptom relief
Last updated Jul 25, 2026 00:00 UTC
-
Psoriasis patients see Real-World quality of life gains with brodalumab
Symptom relief OngoingThis Canadian study follows about 394 adults with plaque psoriasis who are starting brodalumab as part of their regular care. Over 12 months, researchers measure changes in skin-related quality of life, work productivity, and treatment satisfaction. The goal is to understand how …
Sponsor: Bausch Health Americas, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Eczema cream safety watch: 8,000 kids monitored for a decade
Knowledge-focused OngoingThis study follows 8,000 children aged 2 to 17 with eczema who have used Elidel cream (pimecrolimus 1%). Over 10 years, researchers track how many develop cancer, especially lymphoma and thyroid cancer. The goal is to see if the cream raises cancer risk. No new treatment is given…
Sponsor: Bausch Health Americas, Inc. • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:42 UTC